Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) has received an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $27.86.

TRHC has been the topic of several research reports. Piper Jaffray Companies restated a “buy” rating and set a $29.00 price target on shares of Tabula Rasa Healthcare in a report on Tuesday, October 24th. First Analysis assumed coverage on Tabula Rasa Healthcare in a report on Wednesday, November 1st. They issued an “overweight” rating and a $41.00 target price on the stock. Robert W. Baird reiterated an “outperform” rating and issued a $30.00 target price (up from $22.00) on shares of Tabula Rasa Healthcare in a report on Tuesday, October 17th. UBS upped their target price on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, August 30th. Finally, Wells Fargo & Company cut Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and upped their target price for the company from $17.00 to $21.00 in a report on Thursday, September 7th.

Tabula Rasa Healthcare (NASDAQ:TRHC) traded up $1.12 during trading hours on Thursday, hitting $28.63. The stock had a trading volume of 600,306 shares, compared to its average volume of 104,988. The company has a current ratio of 0.73, a quick ratio of 0.66 and a debt-to-equity ratio of 0.47. Tabula Rasa Healthcare has a 52 week low of $11.59 and a 52 week high of $36.80.

Tabula Rasa Healthcare (NASDAQ:TRHC) last released its quarterly earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.02. The company had revenue of $33.27 million for the quarter, compared to analysts’ expectations of $31.76 million. Tabula Rasa Healthcare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.06 earnings per share. sell-side analysts anticipate that Tabula Rasa Healthcare will post 0.05 earnings per share for the current year.

In related news, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $22.10, for a total value of $176,800.00. Following the sale, the insider now directly owns 887,407 shares in the company, valued at $19,611,694.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 45.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Hood River Capital Management LLC boosted its holdings in shares of Tabula Rasa Healthcare by 7.5% during the 2nd quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after buying an additional 57,724 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Tabula Rasa Healthcare by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after buying an additional 27,997 shares in the last quarter. Boston Partners boosted its holdings in shares of Tabula Rasa Healthcare by 17.1% during the 2nd quarter. Boston Partners now owns 235,180 shares of the company’s stock worth $3,540,000 after buying an additional 34,360 shares in the last quarter. Pier Capital LLC bought a new position in shares of Tabula Rasa Healthcare during the 3rd quarter worth approximately $4,151,000. Finally, Wasatch Advisors Inc. bought a new position in shares of Tabula Rasa Healthcare during the 3rd quarter worth approximately $4,047,000. Hedge funds and other institutional investors own 31.85% of the company’s stock.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/tabula-rasa-healthcare-inc-trhc-given-average-rating-of-buy-by-brokerages.html.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.